Absci Corporation
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Sean McClain
- Full Time Employees
- 140
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 18105 SE Mill Plain Boulevard Vancouver WA United States of America 98683
- IPO Date
- Jul 22, 2021
- CIK
- 0001672688
- Website
- absci.com
- Similar Companies
- Business
- Absci Corporation (Nasdaq: ABSI) is a biotechnology company that develops generative AI models and integrated platforms for de novo design of novel proteins, antibodies, and biologics to accelerate drug discovery and development. The company offers its Integrated Drug Creation Platform, which combines generative AI, wet-lab automation, and data sciences; key components include the ABS platform for AI-driven protein design, de novo antibody generation services, and optimization of existing biologics for properties such as developability, stability, and affinity; as well as proprietary datasets and cloud-based software tools for protein engineering. Absci serves pharmaceutical and biotechnology companies targeting oncology, immunology, and metabolic diseases, with operations primarily in the United States and partnerships extending to global markets. Founded in 2011 and headquartered in Vancouver, Washington, the company recently expanded its capabilities through a strategic collaboration with Astellas Pharma in 2024 to co-develop de novo antibodies for an undisclosed target using Absci's generative AI platform; in early 2025, Absci announced a $200 million funding round led by new institutional investors to scale its AI infrastructure and advance multiple programs into preclinical stages; additionally, it launched an upgraded version of its ABS platform featuring enhanced multimodal AI models for faster iteration in therapeutic design.
Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
Wall Street Analysts Predict a 28.3% Upside in ABSCI CORP (ABSI): Here's What You Should Know
Here's Why Absci Corporation (ABSI) is a Great Momentum Stock to Buy
ABSI Soars 36% on Positive Interim Update From Phase I Hair Loss Study
ABSCI CORP (ABSI) Soars 36.0%: Is Further Upside Left in the Stock?
Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program
Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)
MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery
Absci Corporation (ABSI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Absci Corporation (ABSI) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Absci to Participate in Upcoming Investor Conferences
Absci Corporation (ABSI) Q1 2026 Earnings Call Transcript
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates
Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026
Absci Corporation (ABSI) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference
MiMedx Group (NASDAQ:MDXG) & Absci (NASDAQ:ABSI) Head to Head Analysis